Ignite Creation Date:
2025-12-17 @ 9:32 PM
Ignite Modification Date:
2025-12-23 @ 9:59 PM
Study NCT ID:
NCT00741910
Status:
None
Last Update Posted:
2023-11-18 00:00:00
First Post:
2008-08-22 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Extension Study of Semapimod 60 mg IV x 3 Days
Sponsor:
None
Organization:
Study Overview
Official Title:
Extension Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease
Status:
None
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CD06
Brief Summary:
Study CNI-1493-CD06 is an open, single-arm extension studies to CD03 and CD05. CDAI is the only efficacy measure assessed in this study. The safety of multiple courses of semapimod is to be determined by the incidence of clinical and laboratory adverse events.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: